Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed Hodgkin's lymphoma of the classical type (nodular lymphocyte predominance excluded).~* Stage IIB-IV.~* Age 18-70.~* No prior therapy for Hodgkin's lymphoma~* Written informed consent.~* ECOG performance status grades 0-3 (see Appendix E).~* FDG-PET scan before the initiation of treatment.~Exclusion Criteria:~* Prior therapy for Hodgkin's lymphoma.~* Age less than 18 or more than 70.~* Other concomitant or prior malignancies, except basal cell skin carcinoma, or adequately treated carcinoma in situ of the cervix, or any cancer in complete remission for more than 5 years.~* HIV infection.~* Pregnancy or breast-feeding.~* Renal failure (creatinine ≥2 times the normal value), liver failure (AST/ALT or bilirubine ≥ 2.5 times the normal value) or heart failure (NYHA class ≥ 2 or FEV \< 45%).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: OTHER): Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~* PET-2 positive patients will be high-dose salvage treatment;~* PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~* Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~* Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to first arm:~No radiotherapy.
- Arm B (Type: OTHER): Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~* PET-2 positive patients will be high-dose salvage treatment;~* PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~* Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~* Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to second arm:~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).